Endonovo Therapeutics Inc (ENDV)

[Biotech_Tradez]

The quarterly earnings are not broken down in the 10k so it is incorrect in google.

There is mention in the 10k about a change in the derivative liability from all the variable interest rate convertible notes they have, which results in the need to place a value on it for GAAP purposes.

From the 10k:


The increase in other expense during our fiscal year 2021 was primarily the result of re-valuations to reflect liability accounting for convertible notes issued with variable conversion rates. Change in fair value of the Company’s derivative liability decreased by $5.5 million from an income of $5.6 million in 2020 to an income of $0.1 million in 2021, resulting from changes to the inputs to the fair value model. The above was offset by a decrease in interest expense of approximately $1.2 million, the incurrence of $22,162 loss on extinguishment of debt in 2021 as opposed to a $555,430 gain on debt extinguishment in 2020.